• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by TenX Keane Acquisition

    2/13/24 8:09:57 PM ET
    $TENK
    Blank Checks
    Finance
    Get the next $TENK alert in real time by email
    SC 13G 1 d516116dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ___)*

     

     

    TenX Keane Acquisition

    (Name of Issuer)

    Common Shares

    (Title of Class of Securities)

    G8708L104

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d–1(b)

    ☐ Rule 13d–1(c)

    ☐ Rule 13d–1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. G8708L104

     

     (1)   

     Names of reporting persons

     

     Mizuho Financial Group, Inc.

     (2)  

     Check the appropriate box if a member of a group (see instructions)

     (a) ☐  (b) ☒

     

     (3)  

     SEC use only

     

     (4)  

     Citizenship or place of organization

     

     Japan

    Number of

    shares

     beneficially 

    owned by

    each

    reporting

    person

    with:

       (5)   

     Sole voting power

     

     522,030**

       (6)  

     Shared voting power

     

     None

       (7)  

     Sole dispositive power

     

     522,030**

       (8)  

     Shared dispositive power

     

     None

     (9)   

     Aggregate amount beneficially owned by each reporting person

     

     522,030**

    (10)  

     Check if the aggregate amount in Row (9) excludes certain shares (see instructions)

     

    (11)  

     Percent of class represented by amount in Row (9)

     

     5.84%

    (12)  

     Type of reporting person (see instructions)

     

     FI

     

    **

    Mizuho Financial Group, Inc., Mizuho Bank, Ltd. and Mizuho Americas LLC may be deemed to be indirect beneficial owners of said equity securities directly held by Mizuho Securities USA LLC which is their wholly-owned subsidiary.

     


      SCHEDULE 13G   Page 3 of 7

     

    Item 1(a) Name of issuer: TenX Keane Acquisition

    Item 1(b) Address of issuer’s principal executive offices: 420 Lexington Ave, Suite 2446, New York, NY 10170

    2(a) Name of person filing:

    Mizuho Financial Group, Inc.

    2(b) Address or principal business office or, if none, residence:

    1–5–5, Otemachi, Chiyoda–ku, Tokyo 100–8176, Japan

    2(c) Citizenship:

    Japan

    2(d) Title of class of securities:

    Common Shares,

    2(e) CUSIP No.:

    G8708L104

     

    Item 3.

    If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

     

    (a)   ☐

       Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b)   ☐

       Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c)   ☐

       Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d)   ☐

       Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);

    (e)   ☐

       An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);

    (f)   ☐

       An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);

    (g)   ☐

       A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);

    (h)   ☐

       A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

    (i) ☐

       A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);

    (j) ☒

       A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

    (k)   ☐

       Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________________________________

     

    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: 522,030.

    (b) Percent of class: 5.84.


      SCHEDULE 13G   Page 4 of 7

     

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote 522,030.

    (ii) Shared power to vote or to direct the vote None.

    (iii) Sole power to dispose or to direct the disposition of 522,030.

    (iv) Shared power to dispose or to direct the disposition of None.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

    Dissolution of a group requires a response to this item.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    See Exhibit A

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable

     

    Item 10.

    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under §240.14a-11.

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to a parent holding company is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     


    Signatures

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: 02-13-2024    Signature:   

    /s/ Masaaki Kaneko

       Name:    Masaaki Kaneko
       Title:    Managing Director, Global Corporate Function Coordination Dep.


    Power of Attorney

    Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the rules and regulations thereunder, the undersigned, in the undersigned capacity as an authorized representative of Mizuho Financial Group, Inc. (the “Company”), hereby grants full power and authority to Masaaki Kaneko, Managing Director, Head of Global Branches & Subsidiaries Coordination Office, Global Corporate Function Coordination Department, to:

     

      1.

    execute on behalf of the undersigned Form 13G in accordance with Section 13(d) and Section 13(g) of the Exchange Act or any rule or regulation thereunder; .

     

      2.

    do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 13G, complete and execute any amendments, restatements, supplements, and/or exhibits thereto, and timely file such form with the U.S. Securities and Exchange Commission (the “SEC”); and

     

      3.

    take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

    The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney and the rights and powers herein granted.

    The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, is not assuming any of the undersigned’s responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 13 of the Exchange Act.

    This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 13G with respect to the Company’s holdings of and transactions in securities, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

    [Signature page to follow]


    SIGNATURE

    IN WITNESS WHEREOF, the undersigned hereby has caused this Power of Attorney to be executed.

    Mizuho Financial Group, Inc.

     

    Date: 02-13-2024    Signature:   

    /s/ Hidekatsu Take

       Name:    Hidekatsu Take
       Title:    Senior Executive Officer

     

    Get the next $TENK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TENK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TENK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. (CTOR) New York, NY, Aug. 09, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) ("TenX"), a publicly traded special purpose acquisition company, was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 202

      8/9/24 7:30:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

      TenX Keane shareholders voted to approve the previously announced merger with Citius Oncology at an extraordinary general meeting held on August 2, 2024 Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets New York, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TenX Keane Acquisition (NASDAQ:TENKU, TENK, TENKR))) (the "TenX"), a publicly traded special purpose acquisition company, today announced that on August 2, 2024, at the extraordinary general meeting, its shareholders voted to approve the previously announced business combination with the wholly own

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance
    • Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

      Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc. Citius Pharmaceuticals to retain approximately 90% majority control post transaction    Post-merger company expected to trade on Nasdaq as Citius Oncology, Inc. Transaction expected to support commercialization of LYMPHIR, if approved, and exploration of additional oncology assets CRANFORD, N.J., Aug. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane

      8/5/24 8:00:00 AM ET
      $CTXR
      $TENK
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Blank Checks
      Finance

    $TENK
    SEC Filings

    See more
    • SEC Form 25-NSE filed by TenX Keane Acquisition

      25-NSE - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/13/24 4:33:39 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 10-Q filed by TenX Keane Acquisition

      10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      8/9/24 4:22:23 PM ET
      $TENK
      Blank Checks
      Finance
    • TenX Keane Acquisition filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - TenX Keane Acquisition (0001851484) (Filer)

      8/2/24 8:45:17 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dutia Suren G

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:29:05 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Director Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:37 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form 4 filed by Chief Medical Officer Czuczman Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      8/14/24 6:28:05 PM ET
      $TENK
      Blank Checks
      Finance

    $TENK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by TenX Keane Acquisition

      SC 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/15/24 12:53:48 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G/A filed by TenX Keane Acquisition (Amendment)

      SC 13G/A - TenX Keane Acquisition (0001851484) (Subject)

      3/7/24 4:06:26 PM ET
      $TENK
      Blank Checks
      Finance
    • SEC Form SC 13G filed by TenX Keane Acquisition

      SC 13G - TenX Keane Acquisition (0001851484) (Subject)

      2/13/24 8:09:57 PM ET
      $TENK
      Blank Checks
      Finance